Oncotelic Therapeutics dismisses Baker Tilly, hires Rose Snyder & Jacobs as auditor

Oncotelic Therapeutics, Inc.

Baker Tilly's reports for FY 2020 and 2019 contained a going-concern emphasis paragraph.
No disagreements or reportable events occurred with Baker Tilly during the relevant periods.
New auditor RSJ was engaged effective December 21, 2021 for FY 2021 audit.
Company did not consult RSJ on any accounting or auditing matters prior to engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.